Peter Radny

1.8k total citations
19 papers, 1.0k citations indexed

About

Peter Radny is a scholar working on Oncology, Dermatology and Epidemiology. According to data from OpenAlex, Peter Radny has authored 19 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Dermatology and 8 papers in Epidemiology. Recurrent topics in Peter Radny's work include Cutaneous Melanoma Detection and Management (9 papers), Nonmelanoma Skin Cancer Studies (7 papers) and Immunotherapy and Immune Responses (6 papers). Peter Radny is often cited by papers focused on Cutaneous Melanoma Detection and Management (9 papers), Nonmelanoma Skin Cancer Studies (7 papers) and Immunotherapy and Immune Responses (6 papers). Peter Radny collaborates with scholars based in Germany, Austria and Switzerland. Peter Radny's co-authors include Claus Garbe, Thomas Eigentler, Ulrich M. Caroli, Benjamin Weide, Jürgen Bauer, Claudia Pföhler, Annette Pflugfelder, Manfred Schwarz, Jürgen Schäfer and Thomas Nägele and has published in prestigious journals such as Cancer, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

Peter Radny

17 papers receiving 1.0k citations

Peers

Countries citing papers authored by Peter Radny

Since Specialization

Citations

This map shows the geographic impact of Peter Radny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Radny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Radny more than expected).

Fields of papers citing papers by Peter Radny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Radny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Radny. The network helps show where Peter Radny may publish in the future.

Co-authorship network of co-authors of Peter Radny

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Radny. A scholar is included among the top collaborators of Peter Radny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Radny. Peter Radny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Kaliumhydroxid-5 %-Lösung bei aktinischer Keratose 2021 ·Der Hautarzt ·Uwe Reinhold, (unknown), Dietrich Abeck, Ralf W. Denfeld, R. Dominicus, Tatjana Fischer, Peter Radny	0
2	Photodynamic therapy with a 5‐ALA patch does not increase the risk of conversion of actinic keratoses into squamous cell carcinoma 2018 ·Experimental Dermatology ·Uwe Reinhold, Holger Petering, Thomas Dirschka, (unknown), Jens Gille, Hjalmar Kurzen, (unknown), (unknown), (unknown), Peter Radny	7
3	Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study 2010 ·British Journal of Dermatology ·Rolf‐Markus Szeimies, Peter Radny, Michael Sebastian, (unknown), Thomas Dirschka, (unknown), Kristian Reich, G Pabst, David Voss, M. Foguet, (unknown), Hermann Lübbert, Uwe Reinhold	86
4	High response rate after intratumoral treatment with interleukin‐2 2010 ·Cancer ·Benjamin Weide, Evelyna Derhovanessian, Annette Pflugfelder, Thomas Eigentler, Peter Radny, Henning Zelba, Claudia Pföhler, Graham Pawelec, Claus Garbe	113
5	Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up 2010 ·Cancer Immunology Immunotherapy ·Benjamin Weide, Thomas Eigentler, Annette Pflugfelder, Ulrike Leiter, Friedegund Meier, Jürgen Bauer, Diethard Schmidt, Peter Radny, Claudia Pföhler, Claus Garbe	43
6	Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group 2008 ·Melanoma Research ·Thomas Eigentler, Peter Radny, Axel Hauschild, Ralf Gutzmer, R Linse, Claudia Pföhler, Stephan N. Wagner, Dirk Schadendorf, Ulf Ellwanger, Claus Garbe	10
7	Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis 2008 ·Annals of Oncology ·Claus Garbe, Peter Radny, R Linse, Reinhard Dummer, Ralf Gutzmer, Jens Ulrich, Rudolf Stadler, Michael Weichenthal, Thomas Eigentler, Ulf Ellwanger, Axel Hauschild	91
8	A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma 2007 ·Journal of the American Academy of Dermatology ·Thomas Eigentler, (unknown), Benjamin Weide, Helmut Breuninger, Ulrich M. Caroli, Matthias Möhrle, Peter Radny, Claus Garbe	60
9	Hauttumoren transplantierter Patienten 2006 ·Der Hautarzt ·(unknown), Peter Radny, (unknown), Björn Nashan	0
10	Mastix, a known herbal allergen, as causative agent in occupation‐related dermatitis 2006 ·Contact Dermatitis ·A. Volz‐Thomas, (unknown), Leena Bruckner‐Tuderman, D. Nashan, Peter Radny	1
11	Metastatic glucagonoma: Treatment with liver transplantation 2006 ·Journal of the American Academy of Dermatology ·Peter Radny, Thomas Eigentler, (unknown), D. Overkamp, Hans-Rudolf Raab, Richard Viebahn, (unknown), Karl Sotlar, G. Rassner	13
12	Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma 2005 ·European Journal of Cancer ·(unknown), Peter Radny, Thomas Eigentler, Jürgen Schäfer, Christina Pfannenberg, Marius Horger, (unknown), Thomas Nägele, Claus Garbe, Claus D. Claussen, Heinz-Peter Schlemmer	77
13	Fast Whole-Body Assessment of Metastatic Disease Using a Novel Magnetic Resonance Imaging System 2005 ·Investigative Radiology ·H Schlemmer, Jürgen Schäfer, Christina Pfannenberg, Peter Radny, (unknown), (unknown), Thomas Nägele, (unknown), Michael Fenchel, Claus D. Claussen	77
14	Erfahrungen mit der neuen American Joint Committee on Cancer (AJCC)‐Klassifikation des kutanen malignen Melanoms 2005 ·JDDG Journal der Deutschen Dermatologischen Gesellschaft ·Thomas Eigentler, Peter Radny, (unknown), Benjamin Weide, Ulrich M. Caroli, Claus Garbe	6
15	Imiquimod in the treatment of extensive recurrent lentigo maligna 2005 ·Journal of the American Academy of Dermatology ·(unknown), Thomas Eigentler, Peter Radny, Jürgen Bauer, Benjamin Weide, Claus Garbe	27
16	Malignant blue naevus of the scalp 2004 ·The Lancet Oncology ·Peter Radny, (unknown), Thomas Eigentler, Heinz-Peter Schlemmer, Ulrich M. Caroli, (unknown), Claus Garbe	1
17	Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials 2003 ·The Lancet Oncology ·Thomas Eigentler, Ulrich M. Caroli, Peter Radny, Claus Garbe	235
18	Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases 2003 ·British Journal of Cancer ·Peter Radny, Ulrich M. Caroli, Jürgen Bauer, (unknown), (unknown), Thomas Eigentler, Benjamin Weide, Manfred Schwarz, Claus Garbe	140
19	Intralesional rituximab for cutaneous B-cell lymphoma 2001 ·British Journal of Dermatology ·Terri Paul, Peter Radny, S Kröber, Angela Paul, (unknown), Claus Garbe	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact